Bank of America sees Eli Lilly’s Foundayo as preferred oral GLP-1

Eli Lilly and Co (NYSE:LLY) is entering the US market slightly ahead of schedule with its oral GLP-1 weight-loss therapy Foundayo, a move Bank of America...